3 results
To assess if treatment of an intermediate vulnerable coronary lesion in symptomatic patients using a BVS is feasible, results in a more stable plaque, increases vessel luminal area, preserves or improves vasomotion and is not associated with…
Primary:To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatmentSecondary:To assess the efficacy (exacerbations), FEV1 3h post dose, asthma symptoms, safety and tolerability.
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.